CL2021002621A1 - Compuestos de hexahidro-1h-pirazino[1,2-a]pirazina para el tratamiento de una enfermedad autoinmunitaria - Google Patents
Compuestos de hexahidro-1h-pirazino[1,2-a]pirazina para el tratamiento de una enfermedad autoinmunitariaInfo
- Publication number
- CL2021002621A1 CL2021002621A1 CL2021002621A CL2021002621A CL2021002621A1 CL 2021002621 A1 CL2021002621 A1 CL 2021002621A1 CL 2021002621 A CL2021002621 A CL 2021002621A CL 2021002621 A CL2021002621 A CL 2021002621A CL 2021002621 A1 CL2021002621 A1 CL 2021002621A1
- Authority
- CL
- Chile
- Prior art keywords
- pyrazino
- hexahydro
- treatment
- autoimmune disease
- pyrazine compounds
- Prior art date
Links
- 208000023275 Autoimmune disease Diseases 0.000 title 1
- XPPVFPABNTZREL-UHFFFAOYSA-N C1C=2N(CCN1)CCNC=2 Chemical class C1C=2N(CCN1)CCNC=2 XPPVFPABNTZREL-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 239000000203 mixture Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Transplantation (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2019081900 | 2019-04-09 | ||
| CN2019121598 | 2019-11-28 | ||
| CN2020078225 | 2020-03-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2021002621A1 true CL2021002621A1 (es) | 2022-05-13 |
Family
ID=70228042
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2021002621A CL2021002621A1 (es) | 2019-04-09 | 2021-10-06 | Compuestos de hexahidro-1h-pirazino[1,2-a]pirazina para el tratamiento de una enfermedad autoinmunitaria |
Country Status (19)
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11998539B2 (en) | 2019-11-28 | 2024-06-04 | Bayer Aktiengesellschaft | Substituted aminoquinolones as DGKalpha inhibitors for immune activation |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114599652B (zh) * | 2019-10-31 | 2024-07-12 | 豪夫迈·罗氏有限公司 | 用于治疗自身免疫性疾病的氢吡嗪并[1,2-d][1,4]二氮杂䓬化合物 |
| WO2021094301A1 (en) * | 2019-11-12 | 2021-05-20 | F. Hoffmann-La Roche Ag | Hydropyrazino[1,2-b]isoquinoline compounds for the treatment of autoimmune disease |
| EP4061816A1 (en) | 2019-11-19 | 2022-09-28 | F. Hoffmann-La Roche AG | Hydro-1h-pyrrolo[1,2-a]pyrazine compounds for the treatment of autoimmune disease |
| US12503471B2 (en) | 2019-11-19 | 2025-12-23 | Hoffmann-La Roche Inc. | Triazatricycle compounds for the treatment of autoimmune disease |
| CN114761406B (zh) | 2019-12-03 | 2024-04-19 | 豪夫迈·罗氏有限公司 | 用于治疗自身免疫性疾病的氢吡啶并[1,2-a]吡嗪化合物 |
| JP2023533807A (ja) * | 2020-07-14 | 2023-08-04 | エフ. ホフマン-ラ ロシュ アーゲー | 自己免疫疾患の処置のためのヒドロイソキノリン又はヒドロナフチリジン化合物 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2663555T3 (en) * | 2011-01-12 | 2017-03-27 | Ventirx Pharmaceuticals Inc | SUBSTITUTED BENZOAZEPINS AS MODULATORS OF TOLL-LIKE RECEPTORS |
| HRP20171981T1 (hr) | 2012-09-14 | 2018-02-09 | F. Hoffmann - La Roche Ag | Derivati pirazolkarboksamida kao taar modulatora za uporabu u liječenju nekoliko poremećaja poput depresije, dijabetesa i parkinsonove bolesti |
| US9643967B2 (en) * | 2013-12-13 | 2017-05-09 | Takeda Pharmaceutical Company Limited | Pyrrolo[3,2-c]pyridine derivatives as TLR inhibitors |
| MX2021006804A (es) | 2015-12-17 | 2023-01-13 | Merck Patent Gmbh | Antagonistas policiclicos del receptor 7/8 tipo toll (tlr7/8) y uso de los mismos en el tratamiento de trastornos inmunitarios. |
| JP2021527100A (ja) * | 2018-06-13 | 2021-10-11 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | 自己免疫疾患の処置のためのピリジニルヘテロシクリル化合物 |
| CN112752755A (zh) * | 2018-09-27 | 2021-05-04 | 豪夫迈·罗氏有限公司 | 用于治疗自身免疫性疾病的杂环基化合物 |
-
2020
- 2020-04-07 US US17/602,057 patent/US20220340597A1/en not_active Abandoned
- 2020-04-07 PH PH1/2021/552533A patent/PH12021552533A1/en unknown
- 2020-04-07 CR CR20210513A patent/CR20210513A/es unknown
- 2020-04-07 EP EP20717841.9A patent/EP3953356B1/en active Active
- 2020-04-07 AU AU2020272467A patent/AU2020272467A1/en not_active Abandoned
- 2020-04-07 WO PCT/EP2020/059831 patent/WO2020207991A1/en not_active Ceased
- 2020-04-07 BR BR112021020297A patent/BR112021020297A2/pt not_active Application Discontinuation
- 2020-04-07 KR KR1020217036391A patent/KR20210149163A/ko not_active Withdrawn
- 2020-04-07 SG SG11202110401WA patent/SG11202110401WA/en unknown
- 2020-04-07 PE PE2021001647A patent/PE20212178A1/es unknown
- 2020-04-07 MA MA055594A patent/MA55594A/fr unknown
- 2020-04-07 JP JP2021559754A patent/JP7692838B2/ja active Active
- 2020-04-07 MX MX2021012223A patent/MX2021012223A/es unknown
- 2020-04-07 CN CN202080030189.2A patent/CN113710672B/zh active Active
- 2020-04-07 CA CA3135129A patent/CA3135129A1/en active Pending
- 2020-04-08 TW TW109111749A patent/TW202104230A/zh unknown
-
2021
- 2021-09-30 IL IL286870A patent/IL286870A/en unknown
- 2021-09-30 CO CONC2021/0013166A patent/CO2021013166A2/es unknown
- 2021-10-06 CL CL2021002621A patent/CL2021002621A1/es unknown
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11998539B2 (en) | 2019-11-28 | 2024-06-04 | Bayer Aktiengesellschaft | Substituted aminoquinolones as DGKalpha inhibitors for immune activation |
Also Published As
| Publication number | Publication date |
|---|---|
| AU2020272467A1 (en) | 2021-10-14 |
| WO2020207991A1 (en) | 2020-10-15 |
| PH12021552533A1 (en) | 2022-06-20 |
| PE20212178A1 (es) | 2021-11-09 |
| EP3953356C0 (en) | 2023-07-26 |
| EP3953356B1 (en) | 2023-07-26 |
| CO2021013166A2 (es) | 2021-12-10 |
| SG11202110401WA (en) | 2021-10-28 |
| BR112021020297A2 (pt) | 2021-12-14 |
| CN113710672A (zh) | 2021-11-26 |
| IL286870A (en) | 2021-10-31 |
| EP3953356A1 (en) | 2022-02-16 |
| JP7692838B2 (ja) | 2025-06-16 |
| CN113710672B (zh) | 2025-01-03 |
| MA55594A (fr) | 2022-02-16 |
| CR20210513A (es) | 2021-11-02 |
| MX2021012223A (es) | 2021-11-03 |
| CA3135129A1 (en) | 2020-10-15 |
| TW202104230A (zh) | 2021-02-01 |
| KR20210149163A (ko) | 2021-12-08 |
| JP2022527588A (ja) | 2022-06-02 |
| US20220340597A1 (en) | 2022-10-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2025010435A2 (es) | Compuestos tricíclicos para el tratamiento de cáncer | |
| DOP2022000117A (es) | Inhibidores de kras g12c | |
| ECSP22050936A (es) | Compuestos tric?clicos sustituidos | |
| CO2021015698A2 (es) | Moduladores de thr-β y métodos de uso de estos | |
| CL2022000271A1 (es) | Inhibidores de la fosfatasa shp2 de pirazolo(3,4-b)pirazina. | |
| AR126854A1 (es) | Compuestos macrocíclicos para el tratamiento de cáncer | |
| CO2022001094A2 (es) | Pirrolo[2,3-b]pirazinas como inhibidores de hpk1 y uso de las mismas | |
| CO2021013166A2 (es) | Compuestos de hexahidro-1h-pirazino[1,2-a]pirazina para el tratamiento de una enfermedad autoinmunitaria | |
| MX2020008754A (es) | Compuestos farmaceuticos. | |
| MX2018011831A (es) | Antagonistas solubles de receptor de c5aa(c5ar). | |
| MX2021005754A (es) | Derivados de 2,3-dihidro-1h-pirrolo[3,4-c]piridin-1-ona como inhibidores de hpk1 para el tratamiento de cancer. | |
| CO2020014677A2 (es) | Compuestos tetrahidro-1h-pirazino[2,1-a]isoindolilquinolina para el tratamiento de enfermedades autoinmunes | |
| CU20200008A7 (es) | Compuestos de dihidrooxadiazinonas sustituidas útiles en el tratamiento de enfermedades hiperproliferativas, métodos para preparar dichos compuestos y composiciones farmacéuticas que los contienen | |
| AR133266A1 (es) | Macrociclos para el tratamiento de enfermedades autoinmunitarias | |
| AR133199A1 (es) | Macrociclos bicíclicos para el tratamiento de enfermedades autoinmunitarias | |
| ECSP19026973A (es) | Derivados de naftiridinona y su uso en el tratamiento de la arritmia | |
| PY2132400A (es) | COMPUESTOS Y COMPOSICIONES PARA INHIBIR LA ACTIVIDAD DE HIF2a Y SUS MÉTODOS DE USO | |
| MX2020007443A (es) | Derivados de 2,4,6,7-tetrahidro-pirazolo[4,3-d]pirimidin-5-ona y compuestos relacionados como moduladores del receptor c5a para el tratamiento de vasculitis y enfermedades inflamatorias. | |
| CO2022006942A2 (es) | Compuestos de 1,8-naftiridin-2-ona para el tratamiento de una enfermedad autoinmunitaria | |
| CO2024003401A2 (es) | Compuestos de pirazolo[3,4-b]piridina para el tratamiento de enfermedades autoinmunitarias | |
| CU24543B1 (es) | Compuestos bicíclicos 5,6-fusionados y composiciones para el tratamiento de enfermedades parasitarias | |
| DOP2024000096A (es) | Derivados de naftiridinona para el tratamiento de una enfermedad o un trastorno | |
| AR131849A1 (es) | Compuestos tricíclicos para el tratamiento de cáncer | |
| AR131945A1 (es) | Derivados de hidroquinazolina para el tratamiento de una enfermedad o un trastorno |